International Journal on Science and Technology (IJSAT)
E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

Scale-Up and Quality Control Challenges in the Industrial Manufacturing of Nanoformulations: Current Trends and Future Perspectives

Sankalp S Sammasagi [1], Kishori P Sutar[2], Shivaraj Hooli[3]

[1]Research scholar, [2]Assistant Professor, [3]Research scholar
Department of Pharmaceutics, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Nehru Nagar, Belagavi-590010, Karnataka, INDIA.
[1]sankalp.s.sammasagi@gmail.com, [2]kishorisutar@klepharm.edu, [3]shivarajhooli2016@gmail.com

Abstract

Nanoformulations have rapidly transformed pharmaceutical research and industrial drug delivery, offering solutions for enhanced solubility, targeted therapy, and improved pharmacokinetics. However, translating these innovations from laboratory scale to industrial manufacturing presents significant challenges, particularly in process scale-up and quality control. This review critically examines current trends in the industrial production of nanoformulations, including nanoparticles, liposomes, and nanoemulsions, with an emphasis on scalable manufacturing technologies and the maintenance of critical quality attributes. Key obstacles such as reproducibility, batch-to-batch consistency, equipment limitations, and regulatory compliance are discussed, alongside advances in analytical techniques for quality assurance. Case studies of successful industrial-scale nanoformulation products are presented to illustrate practical solutions and ongoing hurdles. Finally, the review explores future perspectives, including the integration of automation, artificial intelligence, and sustainable manufacturing practices, which are poised to address existing limitations and shape the next generation of nanomedicine production. This synthesis aims to guide researchers and industry professionals in overcoming the bottlenecks associated with large-scale nanoformulation manufacturing and ensuring the delivery of safe, effective, and high-quality nanopharmaceuticals.

Keywords: Nanoformulations, Scale-up, Industrial manufacturing

1. Introduction

The pharmaceutical landscape has undergone a paradigm shift with the advent of nanoformulations, which have unlocked new possibilities for drug delivery, targeting, and therapeutic efficacy [1]. Nanoformulations, including nanoparticles, liposomes, nanoemulsions, and solid lipid nanoparticles-enable the encapsulation and controlled release of a wide range of active pharmaceutical ingredients [APIs], thereby overcoming many limitations of conventional dosage forms, such as poor solubility, rapid degradation, and non-specific distribution [2,3].

Over the past decade, significant advancements in nanotechnology have led to the development of innovative drug products that are now making their way from research laboratories to commercial markets.

These nanomedicines offer improved bioavailability, reduced dosing frequency, and the potential for site-specific delivery, making them highly attractive for the treatment of complex diseases such as cancer, infectious diseases, and neurological disorders [4,5]. Despite these promising attributes, the transition from laboratory-scale nanoformulation development to industrial-scale manufacturing poses substantial challenges. Achieving consistent quality, scalability, and regulatory compliance requires a deep understanding of both the physicochemical properties of nanomaterials and the intricacies of pharmaceutical production processes [6].

Key challenges include batch-to-batch variability, process reproducibility, equipment selection, and stringent quality control measures, all of which must be addressed to ensure the safety and efficacy of nanoformulated products [7]. Furthermore, the lack of specific regulatory frameworks and harmonized guidelines for nanoformulations complicates the approval process and necessitates robust evidence of safety and efficacy across different stages of development [8]. The development and optimization of analytical methods for quality control are also critical to guarantee that nanomedicines adhere to regulatory standards and maintain their intended performance throughout their lifecycle [9].

This review aims to provide a comprehensive overview of the current trends and challenges in the industrial manufacturing of nanoformulations, with a particular focus on scale-up strategies and quality control practices. By synthesizing recent advancements, regulatory considerations, and real-world case studies, this article seeks to highlight the critical factors influencing the successful commercialization of nanomedicines and to outline future directions for research and industry practice.

Types of Nanoformulations

Recent advances in nanotechnology have led to the development of diverse nanoformulation types, each with unique structures, properties, and pharmaceutical applications. Here are the major types of nanoformulations:

1. **Nanocrystals**

Nanocrystals are pure drug particles reduced to the nanometer scale, often stabilized by surfactants or polymers. They are primarily used to enhance the solubility and bioavailability of poorly water-soluble drugs, with several products already approved for clinical use [10].

2. **Nanocapsules**

Nanocapsules are vesicular systems with a core-shell structure, where the drug is confined to a cavity surrounded by a polymer membrane. They are particularly useful for protecting sensitive molecules from degradation and for achieving controlled drug release [11].

3. **Nanospheres**

Nanospheres are matrix systems in which the drug is uniformly dispersed throughout a polymer network. These systems are widely used for controlled and sustained drug release, especially in topical and cosmetic formulations [12].

4. Nanosponges

Nanosponges are porous, sponge-like nanoparticles capable of encapsulating both hydrophilic and hydrophobic drugs. They offer enhanced solubility and sustained drug release, and have shown promise in targeted delivery applications [13].

5. Lipid-Based Nanocarriers

Lipid-based systems include liposomes, solid lipid nanoparticles [SLNs], and nanostructured lipid carriers [NLCs]. Liposomes are spherical vesicles with phospholipid bilayers, suitable for both hydrophilic and hydrophobic drugs. SLNs have a solid lipid core and provide controlled release and improved stability, while NLCs combine solid and liquid lipids for higher drug loading and reduced expulsion [14,15].

6. Polymeric Nanoparticles

Polymeric nanoparticles are made from biodegradable polymers such as PLGA or chitosan, enabling controlled and targeted drug delivery. They are widely researched for prolonged drug release, reduced toxicity, and improved therapeutic index [16].

7. Polymeric Micelles

Polymeric micelles are self-assembling colloidal structures formed from amphiphilic block copolymers, featuring a hydrophobic core and hydrophilic shell. They are used to solubilize hydrophobic drugs and enable targeted delivery [17].

8. Dendrimers

Dendrimers are highly branched, tree-like macromolecules with a central core and functional surface groups. Their precise structure allows for versatile drug and gene delivery applications [18].

9. Carbon-Based Nanoparticles

Carbon-based nanomaterials include fullerenes, carbon nanotubes, graphene oxide, and carbon quantum dots. They are used in drug delivery, imaging, biosensing, and tissue engineering due to their unique electrical and mechanical properties [19].

10. Metallic Nanoparticles

Metallic nanoparticles such as gold, silver, iron oxide, and zinc oxide are used for drug delivery, antimicrobial activity, imaging, and diagnostics, owing to their optical and physicochemical properties [20].

11. Semiconductor and Ceramic Nanoparticles

Semiconductor nanoparticles [quantum dots] and ceramic nanoparticles [such as silica and titania] are employed in imaging, diagnostics, and as carriers in advanced drug delivery systems [21].

Industrial Manufacturing Processes for Nanoformulations: Latest Advances and Challenges [2020–2025]

The industrial manufacturing of nanoformulations involves complex processes to ensure scalability, reproducibility, and compliance with regulatory standards. Below is a detailed breakdown of current methods, challenges, and innovations, supported by recent references:

1. Conventional Manufacturing Methods

a] Thin-Film Hydration [Bangham Method]

- **Process:** Lipids dissolved in organic solvents are evaporated to form a thin film, which is hydrated with an aqueous buffer to create multilamellar vesicles [MLVs]. Subsequent downsizing [e.g., extrusion, sonication] produces unilamellar liposomes.
- **Applications:** Liposomes for vaccines [e.g., COVID-19 mRNA vaccines] and cancer therapeutics.
- **Challenges:** Low encapsulation efficiency, batch-to-batch variability, and organic solvent residues.
- **Reference:** Solvent injection and thin-film hydration remain widely used despite scalability limitations [15].

b] Solvent Injection

- **Process:** Lipids dissolved in ethanol or ether are injected into an aqueous phase, forming nanocarriers like liposomes or lipid nanoparticles [LNPs].
- **Applications:** LNPs for mRNA vaccines [e.g., Pfizer-BioNTech, Moderna].
- **Advantages:** Simplicity, rapid production.
- **Challenges:** Requires solvent removal and purification steps [16].

c] High-Pressure Homogenization

- **Process:** Forces lipid-drug mixtures through narrow channels under high pressure to form nanoparticles [e.g., solid lipid nanoparticles, SLNs].
- **Applications:** Industrial production of nanocrystals and lipid-based formulations.
- **Reference:** Key for scalable production of liposomes and SLNs [17].

2. Advanced Manufacturing Technologies

a] Microfluidic Mixing

- **Process:** Precise control of nanoprecipitation using staggered herringbone micromixers, T-junction mixers, or glass capillaries. Enables continuous production of polymeric, lipid, and inorganic nanoparticles.
- **Advantages:** High reproducibility, narrow size distribution, and scalability.

- **Applications:** mRNA-LNPs, polymeric micelles, and nanocrystals.
- **Reference:** Microfluidics addresses scalability challenges in nanomedicine production [18].

b] Spray Drying

- **Process:** Converts nanoparticle suspensions into dry powders, improving stability and shelf life.
- **Applications:** Inhalable nanomedicines and oral solid dosages.
- **Challenges:** Thermal degradation risks; requires optimization of nozzle design and feed rates [19].

c] Supercritical Fluid Technology

- **Process:** Uses supercritical CO_2 to dissolve lipids or polymers, followed by rapid depressurization to form nanoparticles.
- **Advantages:** Solvent-free, eco-friendly, and scalable.
- **Applications:** Protein-based nanoparticles and inhalable formulations [20].

Analytical Methods for Quality Control of Nanoformulations

Nanoformulations require rigorous characterization to ensure safety, efficacy, and compliance with regulatory standards. Below is a detailed overview of analytical methods used to evaluate critical quality attributes [CQAs] such as particle size, zeta potential, drug loading, encapsulation efficiency, and stability.

1. Particle Size and Distribution

a] Dynamic Light Scattering [DLS]

- **Principle:** Measures hydrodynamic diameter via Brownian motion-induced light scattering fluctuations.
- **Application:** Determines size distribution and polydispersity index [PDI] in liquid suspensions.
- **Advantages:** Fast, non-destructive, minimal sample preparation.
- **Limitations:**
    - Assumes spherical particles; less accurate for polydisperse/aggregated samples.
    - Limited to particles <5 µm; sensitive to dust/contaminants.

b] Cryogenic Transmission Electron Microscopy [Cryo-TEM]

- **Principle:** Visualizes nanoparticles in vitrified ice to preserve native structure.
- **Application:** Provides direct imaging of size, morphology, lamellarity [e.g., liposomes].
- **Advantages:** High resolution [≈0.2 nm]; ideal for complex samples.
- **Limitations:** Requires expertise; time-consuming sample preparation.

c] Analytical Ultracentrifugation [AUC]

- **Principle:** Sedimentation velocity analysis under centrifugal force.
- **Application:** Measures size distribution and density.
- **Advantages:** No calibration standards needed; works for dense particles.
- **Limitations:** Low throughput; expensive instrumentation.

d] Nanoparticle Tracking Analysis [NTA]

- **Principle:** Tracks Brownian motion of individual particles via light scattering.
- **Application:** Quantifies size distribution and concentration.
- **Advantages:** Works for polydisperse samples; low sample volume.
- **Limitations:** Limited to dilute suspensions.

2. Zeta Potential

a] Electrophoretic Light Scattering [ELS]

- **Principle:** Measures particle mobility in an electric field via Doppler shift.
- **Application:** Determines surface charge [zeta potential] to predict colloidal stability.
- **Advantages:** Fast; works in polar solvents [e.g., water, chloroform].
- **Limitations:** Sensitive to ionic strength; requires calibration.

3. Drug Loading and Encapsulation Efficiency

a] High-Performance Liquid Chromatography [HPLC]

- **Principle:** Separates and quantifies free vs. encapsulated drug.
- **Application:** Measures drug loading [%] and encapsulation efficiency [%].
- **Advantages:** High sensitivity and specificity.
- **Limitations:** Requires method validation; time-consuming.

b] UV-Vis Spectroscopy

- **Principle:** Quantifies drug concentration via absorbance.
- **Application:** Used with centrifugation/ultrafiltration to separate free drug.
- **Advantages:** Rapid; cost-effective.
- **Limitations:** Interference from excipients.

4. In Vitro Drug Release

a] Dialysis Bag Method

- **Principle:** Drug diffusion through a semipermeable membrane into release medium.
- **Application:** Simulates sustained release profiles [e.g., 80% release over 24h].
- **Advantages:** Simple; mimics physiological conditions.
- **Limitations:** Membrane adsorption artifacts.

b] Franz Diffusion Cells

- **Principle:** Measures drug permeation across synthetic membranes.
- **Application:** Evaluates release kinetics for topical formulations.
- **Advantages:** Reproducible; suitable for low-solubility drugs.
- **Limitations:** Requires large sample volumes.

5. Stability Testing

a] Accelerated Stability Studies

- **Principle:** Exposes samples to elevated temperature/humidity [e.g., 40°C/75% RH].
- **Application:** Predicts shelf life and identifies degradation pathways.
- **Parameters Monitored:** Particle size, drug content, pH.

b] Differential Scanning Calorimetry [DSC]

- **Principle:** Measures thermal transitions [e.g., melting, crystallization].
- **Application:** Detects physical stability [e.g., lipid crystallization in LNPs].
- **Advantages:** Identifies polymorphic changes.
- **Limitations:** Requires crystalline components.

6. Surface Chemistry and Purity

a] Fourier Transform Infrared Spectroscopy [FTIR]

- **Principle:** Detects functional groups via infrared absorption.
- **Application:** Confirms surface modifications [e.g., PEGylation].
- **Advantages:** Non-destructive; minimal sample prep.
- **Limitations:** Limited to surface-sensitive analysis.

b] X-ray Photoelectron Spectroscopy [XPS]

- **Principle:** Analyzes elemental composition and chemical states.
- **Application:** Validates coating integrity [e.g., gold nanoparticles].
- **Advantages:** Quantitative surface analysis [≈10 nm depth].
- **Limitations:** Requires high vacuum.

7. Residual Solvents and Impurities

a] Gas Chromatography [GC]

- **Principle:** Separates volatile compounds via vaporization.
- **Application:** Quantifies residual solvents [e.g., chloroform].
- **Advantages:** High sensitivity [ppm level].
- **Limitations:** Limited to volatile analytes.

b] Inductively Coupled Plasma Mass Spectrometry [ICP-MS]

- **Principle:** Detects metal impurities via ionized plasma.
- **Application:** Quantifies elemental contaminants [e.g., Au, Ag].
- **Advantages:** Ultra-trace detection [ppb level].
- **Limitations:** Expensive instrumentation.

Regulatory Considerations

- **EMA/FDA Guidelines:** Require documentation of CQAs, process validation, and stability data.
- **ICH Harmonization:** Q2[R1] for analytical method validation.
- **Case Study:** DLS and cryo-TEM are mandated for lipid nanoparticle [LNP] characterization in mRNA vaccines.

3. Key Challenges in Industrial Manufacturing

a] Scalability

Scaling up from laboratory to industrial production can compromise critical quality attributes [CQAs] such as particle size and drug loading. The adoption of Process Analytical Technologies [PAT], including real-time monitoring tools like photon density wave spectroscopy and optofluidic force induction [OF2i], is helping to address these challenges [21].

b] Quality Control

Ensuring consistent particle size, polydispersity index [PDI], zeta potential, and drug loading is essential. Analytical techniques such as dynamic light scattering [DLS] and transmission electron microscopy [TEM] are routinely used for quality assessment [22].

c] Regulatory Compliance

Regulatory agencies such as the EMA and FDA require robust documentation of manufacturing processes, quality control, and batch consistency. The experience with Doxil® [liposomal doxorubicin] highlighted the importance of strict process control to prevent issues like crystallization during scale-up [23].

4. Emerging Trends [2020–2025]

a] Continuous Manufacturing

Continuous processes, particularly using microfluidic systems, are reducing batch variability and increasing efficiency in nanoformulation production [18].

b] Green Nanomanufacturing

There is a growing focus on solvent-free and sustainable manufacturing methods, such as supercritical fluid technology, to minimize environmental impact [20].

c] AI-Driven Optimization

Artificial intelligence and machine learning are being integrated into process development to optimize parameters and predict outcomes, further enhancing scalability and reproducibility [24].

5. Case Studies

1. Doxil® [Liposomal Doxorubicin]: Lessons in Liposome Scale-Up

Doxil® is the first FDA-approved nanomedicine, consisting of doxorubicin encapsulated in PEGylated liposomes. The scale-up of Doxil® production highlighted several critical challenges:

- Key Challenges: Ensuring batch-to-batch reproducibility, maintaining consistent particle size and encapsulation efficiency, and preventing drug crystallization during large-scale production.
- Emerging Strategies: Implementation of microfluidics for controlled mixing, iterative optimization of critical process parameters [e.g., lipid composition, hydration time], and advanced computer modeling for process scale-up.
- Impact: These strategies enabled robust, quality-controlled production at commercial scale, opening the path for large-batch manufacturing and reliable clinical supply. The Doxil® case also underscored the importance of continuous process monitoring and regulatory compliance for nanotherapeutics [25].

2. Industrial-Scale Production of PLGA Nanomedicines via Inline Sonication

Poly[lactic-co-glycolic acid] [PLGA] nanoparticles are widely researched for drug delivery, but their clinical translation has been hampered by scale-up challenges:

- Manufacturing Solution: Development of an inline sonication process, allowing continuous and scalable production of PLGA nanoparticles with narrow size distribution [mean diameter ~150 nm, PDI < 0.2].

- Downstream Processing: Use of tangential flow filtration [TFF] for purification and concentration, and lyophilization for stable storage.
- Outcomes: Achieved high encapsulation efficiencies for ritonavir [49.5%] and celecoxib [80.3%], with production rates of 84 g/h. The process is adaptable for continuous, industrial-scale manufacturing and is compatible with GMP standards[26].

3. Liposomal ASD-005: Parenteral Sustained Delivery

A recent case study focused on the development and characterization of a PEGylated liposomal formulation for ASD-005, a therapeutic agent:

- Preparation Methods: Compared film hydration, solvent injection, high-pressure homogenization, and extrusion for liposome formation.
- Optimization: The F3 formulation [using DMPC:DMPG:DSPE] achieved the highest encapsulation efficiency and drug loading, with particle sizes in the 100–150 nm range.
- Characterization: Utilized SEM, DLS, and DSC to confirm morphology and stability. In vitro release and animal pharmacokinetic studies demonstrated sustained drug release and favorable stability profiles.
- Significance: The study highlights the importance of method selection and optimization for achieving industrially relevant, stable, and scalable liposomal products[27].

4. Lipid Nanoparticle [LNP] Self-Assembly for mRNA Vaccine Production

LNPs are central to the success of mRNA vaccines [e.g., for COVID-19]:

- Technical Challenge: Achieving precise control over LNP size, as smaller particles enhance tissue penetration and delivery efficacy.
- Solution: Use of microfluidic mixers, with computational fluid dynamics [CFD] and population balance modeling [PBM] to optimize mixing times, flow rates, and flow rate ratios.
- Industrial Impact: Simulations guided rapid optimization of mixer designs and operating protocols, enabling scalable, GMP-compliant LNP production with tunable size distributions for clinical and commercial use[28].

5. High-Throughput Microfluidic Layer-by-Layer Nanoparticle Assembly for Cancer Therapy

Researchers developed a scalable method to manufacture polymer-coated, layer-by-layer nanoparticles for targeted cancer therapy:

- Innovation: Microfluidic mixing device enables sequential, automated addition of polymer layers, eliminating manual steps and reducing the need for purification after each layer.
- GMP Integration: The process is compatible with good manufacturing practice [GMP] and allows for rapid, high-throughput production.

- Clinical Relevance: The new method produced 15 mg of nanoparticles in minutes [enough for ~50 doses], suitable for clinical trials. In mouse models, IL-12-coated nanoparticles activated immune cells and delayed tumor growth, showing comparable efficacy to traditional methods but with greater scalability and consistency[29].

Challenges in Scaling Up Nanoformulation Manufacturing: Latest Insights [2020–2024]

Scaling up nanoformulations from laboratory to industrial production remains a critical bottleneck in translating nanomedicines to clinical and commercial use. Below is a detailed analysis of key challenges, supported by recent case studies and references.

1. Physicochemical and Structural Changes During Scale-Up

Nanoformulations often exhibit altered physicochemical properties [e.g., particle size, stability, drug loading] when transitioning from lab to industrial processes. For example:

- **Particle Aggregation:** Increased batch sizes can disrupt colloidal stability, leading to aggregation and reduced bioavailability.
- **Drug Leakage:** Lipid nanoparticles [LNPs] may lose mRNA payloads during large-scale mixing due to shear stress.
- **Crystallization:** Liposomal doxorubicin [Doxil®] faced crystallization issues during hydration steps, necessitating strict process controls [30].

Key Drivers:

- Loss of precision in mixing ratios, temperature, and shear forces.
- Incompatibility of lab-scale methods [e.g., manual pipetting] with industrial equipment [31].

2. Batch-to-Batch Variability and Reproducibility

Achieving consistency in particle size, polydispersity index [PDI], and drug encapsulation remains a major hurdle:

- **Lipid Nanoparticles [LNPs]:** Variations in lipid composition or mixing speeds during scale-up can alter LNP size [70–150 nm target] and mRNA delivery efficiency.
- **Polymeric Nanoparticles:** PLGA nanoparticles require iterative optimization of solvent removal and lyophilization steps to prevent batch failures [32].

Case Study:

- **mRNA-LNP Vaccines:** Microfluidic mixing enabled tunable particle sizes [80–120 nm] in small batches but required computational fluid dynamics [CFD] modeling to maintain consistency at 1,000-liter scales [33].

Emerging Solutions:

- **Microfluidics:** Enables continuous production with precise control [e.g., 15 mg/min for layered nanoparticles] [34].

- **Supercritical CO_2:** Solvent-free synthesis of PLGA nanoparticles, reducing environmental impact [35].

4. Regulatory and Quality Control Hurdles

1. Lack of Harmonized Definitions and Guidelines

- **Definitional Ambiguity:** Regulatory agencies worldwide lack consensus on what constitutes a "nanomaterial." For example:
  - **FDA:** Defines nanomaterials as engineered materials with at least one dimension ≤100 nm *or* exhibiting dimension-dependent properties.
  - **EMA:** Focuses on "novel" nanomaterials, excluding naturally occurring nanoparticles [e.g., proteins].
  - **India's CDSCO:** Defines nanopharmaceuticals as formulations with altered nanoscale properties impacting safety/efficacy.
- **Impact:** Confusion in classification delays approvals and increases development costs. For example, lipid nanoparticles [LNPs] for mRNA vaccines faced ambiguity in early regulatory submissions.

2. Characterization and Quality Control Challenges

- **Critical Quality Attributes [CQAs]:**
  - **Size, PDI, Zeta Potential:** Minor variations can alter biodistribution and efficacy [e.g., Doxil® liposomes require strict size control of 80–100 nm].
  - **Drug Loading/Release:** Complex to standardize for nanoformulations like polymeric micelles or dendrimers [36].
- **Analytical Limitations:**
  - Traditional methods [e.g., DLS] may fail to detect aggregation or surface modifications.
  - **EMA Recommendation:** Advanced tools like cryo-TEM and AFM for precise characterization.

3. Safety and Toxicity Concerns

- **Nanotoxicity:**
  - Long-term accumulation in organs [e.g., liver, spleen] raises safety flags.
  - **Example:** Iron oxide nanoparticles were withdrawn due to oxidative stress risks.
- **Immunogenicity:**
  - PEGylated nanoparticles can trigger anti-PEG antibodies, reducing efficacy [e.g., COVID-19 vaccine hypersensitivity].

- **Regulatory Requirements:**
    - Extended preclinical studies for biodistribution, degradation, and immunotoxicity [37].

4. Scalability and Manufacturing Consistency

- **Batch-to-Batch Variability:**
    - Industrial-scale processes [e.g., microfluidics] must maintain CQAs. LNPs for mRNA vaccines required CFD modeling to ensure consistency at 1,000-liter scales.
- **GMP Compliance:**
    - Strict documentation of raw materials, process parameters, and sterilization methods.
    - **EMA Warning:** 30% of nanomedicine applications fail due to inadequate manufacturing data.

5. Classification and Borderline Products

- **Drug vs. Device:**
    - Nanoparticles with dual roles [e.g., diagnostic + therapeutic] face ambiguous regulatory pathways.
    - **Case Study:** NBTXR3 [radioenhancer for cancer] classified as a medical device in the EU but as a drug in the U.S., complicating global approvals6.
- **Combination Products:**
    - Nanoformulations with biologics [e.g., mRNA-LNPs] require dual compliance with biologics and nanotechnology guidelines [38].

6. Clinical Trial Design and Evidence Generation

- **Pharmacokinetics [PK]:**
    - Nanoparticles exhibit non-linear PK, requiring novel trial designs.
- **Bioequivalence for Generics:**
    - Complex to demonstrate equivalence for follow-on nanomedicines [e.g., liposomal doxorubicin generics].
- **EMA/FDA Demand:**
    - Long-term safety data [5–10 years] for chronic use nanoformulations.

7. Global Harmonization Gaps

- **Divergent Standards:**
    - **EU:** Requires environmental risk assessments for nanomaterials.
    - **U.S.:** Focuses on product-specific risks under the "Case-by-Case" approach.

  - **India:** New 2025 guidelines emphasize affordability but lack nano-specific toxicity protocols.
- **Impact:** Developers face redundant testing and documentation for multi-regional approvals.

Strategies to Overcome Regulatory Hurdles

1. **Early Engagement with Regulators:**
   - Use FDA's **INTERACT** or EMA's **SAWP** programs for pre-submission feedback [39].
2. **Quality by Design [QbD]:**
   - Define CQAs early [e.g., particle size, stability] and use DoE [Design of Experiments] for process optimization.
3. **Advanced Analytics:**
   - Implement **NanoPAT** tools [e.g., optofluidic force induction] for real-time monitoring.
4. **Global Collaboration:**
   - Align with initiatives like the **International Council for Harmonisation [ICH]** to standardize guidelines.

Case Studies of Regulatory Approvals for Nanoformulations

Below are detailed case studies of regulatory approvals for nanoformulations, highlighting challenges, strategies, and outcomes. These examples illustrate how regulatory agencies [FDA, EMA] evaluate nanomedicines and provide insights for industrial-scale manufacturing and compliance.

1. Doxil® [Liposomal Doxorubicin] [40]

- **Product:** PEGylated liposomal doxorubicin for ovarian cancer and Kaposi's sarcoma.
- **Regulatory Pathway:**
  - **FDA Approval [1995]:** Approved via New Drug Application [NDA] under Section 505[b][1].
  - **EMA Approval [1996]:** Authorized under Article 8[3] of Directive 2001/83/EC.
- **Challenges:**
  - **Scale-Up Issues:** Initial batches faced crystallization due to improper hydration steps, leading to recalls.
  - **Quality Control:** Strict monitoring of particle size [80–100 nm] and stability was required to prevent aggregation.
- **Outcome:**
  - Revised manufacturing protocols with real-time monitoring [e.g., dynamic light scattering] ensured batch consistency.

- Post-marketing studies confirmed long-term safety and efficacy, solidifying Doxil® as a benchmark for liposomal drugs.

2. Onpattro® [Patisiran, siRNA-LNPs] [41]

- **Product:** Lipid nanoparticles [LNPs] delivering siRNA for hereditary transthyretin-mediated amyloidosis.
- **Regulatory Pathway:**
  - **FDA Approval [2018]:** First siRNA therapeutic approved via Biologics License Application [BLA].
  - **EMA Approval [2018]:** Authorized under centralized procedure [CP].
- **Challenges:**
  - **Novel Excipients:** Ionizable lipid [DLin-MC3-DMA] required extensive safety data as a novel excipient.
  - **Immunogenicity:** Anti-PEG antibodies raised concerns, necessitating immunotoxicity studies.
- **Outcome:**
  - Demonstrated reduced serum TTR levels by 81% in clinical trials.
  - Set a precedent for RNA-LNP therapeutics, influencing Comirnaty's approval.

3. Comirnaty® [mRNA-LNPs for COVID-19] [42]

- **Product:** mRNA-LNPs encoding SARS-CoV-2 spike protein.
- **Regulatory Pathway:**
  - **FDA Approval [2021]:** Emergency Use Authorization [EUA] under BLA, later converted to full approval.
  - **EMA Approval [2021]:** Conditional Marketing Authorization [CMA] under Regulation [EC] No 726/2004.
- **Challenges:**
  - **Scalability:** Rapid scale-up to 1,000-liter batches required CFD modeling to maintain LNP size [80–120 nm].
  - **Cold Chain:** -70°C storage necessitated global logistics adaptations.
- **Outcome:**
  - First mRNA vaccine approved globally, with >90% efficacy in Phase III trials.
  - Post-marketing surveillance confirmed safety in billions of doses.

4. CALAA-01 [siRNA-Polymer Nanoparticles] [43]

- **Product:** Cyclodextrin-based polymer nanoparticles delivering siRNA targeting ribonucleotide reductase.

- **Regulatory Pathway:**
  - **FDA IND [2008]:** First targeted siRNA nanoparticle to enter Phase I trials under Investigational New Drug [IND] application.
- **Challenges:**
  - **Novel Platform:** Lack of precedents for siRNA-polymer nanoparticles required extensive preclinical characterization.
  - **Manufacturing Consistency:** Lab-scale processes [e.g., solvent displacement] needed adaptation for GMP compliance.
- **Outcome:**
  - Demonstrated proof-of-concept for targeted siRNA delivery but faced financial discontinuation post-Phase I.
  - Informed later RNA-LNP development [e.g., Onpattro, Comirnaty].

Key Lessons Learned

1. **Early Regulatory Engagement:**
   - Onpattro and Comirnaty leveraged pre-IND meetings [FDA] and scientific advice [EMA] to clarify excipient classification and stability requirements
2. **Robust Process Controls:**
   - Doxil® recalls emphasized the need for real-time monitoring of particle size and stability during scale-up
3. **Adaptive Pathways for Novel Technologies:**
   - CALAA-01's IND approval highlighted flexibility in regulatory frameworks for pioneering nanotherapeutics
4. **Global Harmonization Gaps:**
   - Comirnaty's lipids were classified as excipients in the EU but required additional data as novel components in the U.S.

Implications for Industry:

For aspiring production managers, understanding these regulatory challenges is critical. Focus on **process robustness**, **QbD frameworks**, and **early regulatory dialogue** to streamline approvals and ensure commercial success.

Recent Issues:

- **Doxil® Recalls:** Crystallization due to improper hydration steps highlighted the need for real-time monitoring [44].
- **LNPs for mRNA Vaccines:** Cold-chain requirements [-70°C storage] added logistical complexity [45].

Case studies of successful developed nanoformulation

Here are **detailed case studies of successfully developed nanoformulations**, including approved drugs and industrial collaborations, based on search results and recent literature:

1. Doxil® [Liposomal Doxorubicin] [44]

- **Nanoformulation Type:** PEGylated liposomes.
- **Application:** Treatment of ovarian cancer and Kaposi's sarcoma.
- **Development Highlights:**
  - First FDA-approved nanomedicine [1995].
  - Overcame challenges like drug leakage and instability using PEGylation to enhance circulation time.
  - **Key Outcome:** Demonstrated reduced cardiotoxicity compared to free doxorubicin.
- **Challenges:** Crystallization during scale-up required strict process controls.
- **Reference:** PMC6391637, PMC5720487

2. Onpattro® [Patisiran, siRNA-LNPs] [41]

- **Nanoformulation Type:** Lipid nanoparticles [LNPs] with ionizable lipids.
- **Application:** Hereditary transthyretin-mediated amyloidosis.
- **Development Highlights:**
  - First siRNA therapeutic approved by the FDA [2018].
  - LNPs enabled targeted delivery to hepatocytes, reducing toxic protein buildup.
  - **Key Outcome:** 81% reduction in serum transthyretin levels in clinical trials.
- **Challenges:** Required novel excipient safety data for ionizable lipids.
- **Reference:** PMC7611893

3. Abraxane® [Albumin-Bound Paclitaxel] [46]

- **Nanoformulation Type:** Albumin-stabilized paclitaxel nanoparticles [~130 nm].
- **Application:** Metastatic breast cancer, pancreatic cancer.
- **Development Highlights:**

  - Avoided toxic solvents [e.g., Cremophor EL] used in traditional paclitaxel.
  - **Key Outcome:** Higher tolerated doses and improved efficacy over solvent-based formulations.
- **Challenges:** Scaling albumin-drug binding processes.
- **Reference:** PMC5720487

4. Vyxeos® [Liposomal Daunorubicin/Cytarabine] [47]

- **Nanoformulation Type:** Liposomes co-encapsulating two chemotherapeutics.
- **Application:** Acute myeloid leukemia [AML].
- **Development Highlights:**
  - Fixed 1:5 ratio of daunorubicin:cytarabine for synergistic effect.
  - **Key Outcome:** Improved survival rates in elderly AML patients.
- **Challenges:** Ensuring drug ratio consistency during scale-up.
- **Reference:** PMC7611893

5. NanoComposix Case Studies

a] PLGA Nanoparticles for Immunotherapy

- **Collaboration:** Developed GMP-grade PLGA nanoparticles for Phase I/II trials.
- **Key Steps:**
  - Integrated client's API into nanoparticles.
  - Scaled from lab to manufacturing, ensuring stability and sterility.
- **Outcome:** Successful production of clinical trial material.

b] Photothermal Silver Nanoplates for Hair Removal

- **Application:** Topical treatment [Sienna Biopharmaceuticals].
- **Key Steps:**
  - Optimized silica-coated silver nanoplates under R&D and GMP controls.
  - Validated photothermal efficiency in pilot studies.
- **Outcome:** Prototype used in clinical studies for hair removal.

c] Gold Nanoparticle Conjugates for Cancer Therapy

- **Application:** Oligonucleotide delivery.
- **Key Steps:**
  - Designed gold nanoparticles with covalent oligonucleotide binding.
  - Developed a lateral flow assay for rapid quality testing.
- **Outcome:** Enhanced drug functionality and stability [48].

6. mRNA-LNPs [COVID-19 Vaccines]

- **Nanoformulation Type:** Lipid nanoparticles [LNPs] with ionizable lipids.
- **Application:** SARS-CoV-2 mRNA vaccines [Pfizer-BioNTech, Moderna].
- **Development Highlights:**
  - Microfluidic mixing enabled rapid scale-up to 1,000-liter batches.
  - **Key Outcome:** >90% efficacy in Phase III trials; billions of doses administered globally.
- **Challenges:** Cold-chain logistics [-70°C storage].

Key Lessons from Successful Nanoformulations

1. **Scalability:** Microfluidics and QbD frameworks resolved batch inconsistencies [e.g., mRNA-LNPs].
2. **Regulatory Strategy:** Early engagement with FDA/EMA streamlined approvals [e.g., Onpattro].
3. **Clinical Impact:** Reduced toxicity and improved efficacy over conventional therapies [e.g., Doxil®, Abraxane].

Economic and Supply Chain Barriers in Nanoformulation Manufacturing [2020–2025]

The industrial-scale production of nanoformulations faces significant economic and supply chain challenges, which hinder commercialization and accessibility. Below is a detailed analysis based on recent reports and case studies:

1. Economic Barriers

a] High Capital and Operational Costs

- **Upfront Investments:** Industrial-scale equipment [e.g., microfluidic systems, lyophilizers] requires **$2M–$5M+** in initial costs.

- **Raw Material Expenses:** Specialty lipids [e.g., ionizable lipids for mRNA-LNPs] and polymers [e.g., PLGA] are costly due to limited suppliers and complex synthesis.
- **Regulatory Compliance:** Meeting FDA/EMA guidelines for nanomedicine safety and quality adds **20–30%** to development costs.

Case Study:

- **Lipid Nanoparticles [LNPs]:** The global LNP market faces cost pressures due to high-purity lipid requirements [$500–$1,000/kg] and ultra-cold storage needs [-70°C] for mRNA vaccines

b] Uncertain Return on Investment [ROI]

- **Low Profit Margins:** Nanoformulations targeting rare diseases or small patient populations struggle to justify R&D costs.
- **Market Competition:** Generics for blockbuster nanomedicines [e.g., liposomal doxorubicin] undercut pricing by **40–60%**

c] Funding Gaps

- **Pharmaceutical Industry Hesitation:** Only **15%** of pharma companies invest in nanomedicine R&D due to perceived risks
- **Venture Capital Reluctance:** Investors prioritize therapies with clear regulatory pathways and large markets, sidelining complex nanoformulations

2. Supply Chain Barriers

a] Raw Material Shortages

- **Lipids and Polymers:** The 2020–2023 mRNA vaccine surge caused **global lipid shortages**, delaying non-COVID nanomedicine trials
- **Metal Salts:** Iron[III] nitrate and sulfate, critical for MOF-based nanoformulations [e.g., MIL-100], face supply bottlenecks due to geopolitical tensions

b] Logistical Challenges

- **Cold Chain Requirements:** LNPs and protein-based nanoformulations require temperature-controlled logistics, increasing costs by **50–70%**
- **Fragile Nanoparticles:** Aggregation during transport necessitates specialized packaging, raising expenses

c] Geographic Concentration

- **Supplier Monopolies:** Over **80%** of ionizable lipids are produced by 3–4 companies in the U.S. and EU, creating dependency risks

- **Manufacturing Hubs:** Limited GMP facilities in Asia-Pacific and Africa delay global distribution

Table 01: Interplay Between Economic and Supply Chain Issues

Challenge	Economic Impact	Supply Chain Impact
Lipid Shortages	Delayed trials → Lost revenue [$10M+/study]	Reliance on spot markets → 300% price hikes
Cold Chain Logistics	2–3x higher distribution costs	Limited cold storage in LMICs → 30% product loss
Regulatory Delays	$500k–$2M+ per additional trial phase	Batch expiration during approvals → 15–20% waste

4. Strategies to Mitigate Barriers

a] Cost Reduction

- **Green Manufacturing:** Supercritical CO_2-based synthesis reduces solvent use and cuts MIL-100[Fe] production costs to **<$30/kg**
- **AI-Driven Optimization:** Machine learning models lower trial-and-error R&D costs by **40%**

b] Supply Chain Resilience

- **Diversified Sourcing:** Partnerships with regional suppliers [e.g., India's CDSCO-compliant lipid producers] reduce dependency
- **Modular Production:** Portable microfluidic systems enable decentralized LNP manufacturing, avoiding cold-chain bottlenecks.

c] Policy Interventions

- **Subsidies:** EU's **Horizon Europe** funds cover **50–70%** of nanoformulation scale-up costs for SMEs
- **Stockpiling:** National reserves for critical nanomaterials [e.g., lipids, PLGA] prevent shortages during crises

Future Perspectives in Nanoformulation Manufacturing

Emerging Technologies: Automation, AI, and Continuous Manufacturing

- **Automation & Continuous Manufacturing**: Automated and continuous manufacturing systems, such as computer-controlled microfluidic devices and continuous jet mixers, are transforming nanoparticle production. These platforms enable precise control over nanoparticle size, reproducibility, and scalability, while minimizing human intervention and error. For example, automated continuous jet mixing [CJM] systems can produce polymeric nanoparticles with tunable sizes in a stable, hands-off process-critical for industrial translation and site-specific drug delivery Continuous manufacturing [CM] is increasingly adopted in RNA therapeutics and nanomedicine,

allowing real-time process monitoring, rapid scale-up, and seamless integration of synthesis, purification, and formulation. CM reduces production timelines, improves quality, and supports modular, flexible manufacturing for both small-batch personalized medicines and large-scale vaccines.

- **Artificial Intelligence [AI]:** AI and machine learning are revolutionizing nanomedicine by enabling data-driven design, synthesis optimization, and real-time process control. AI algorithms can predict optimal materials, reaction conditions, and nanoparticle properties, reducing experimental workload and accelerating development. AI-powered sensors and data analytics also facilitate real-time monitoring and adjustment during nanoparticle synthesis, ensuring batch consistency and quality. Autonomous manufacturing platforms, integrating AI for process optimization and quality assurance, are emerging as a new standard for tailored, high-quality drug-loaded nanoparticles

Sustainability and Green Manufacturing

- **Green Nanotechnology:** The pharmaceutical industry is increasingly adopting green nanotechnology principles to minimize environmental impact. This includes using renewable and biodegradable materials [e.g., plant-derived polysaccharides, biopolymers], water-based or solvent-free synthesis, and energy-efficient techniques like microwave or ultrasound-assisted synthesis. Green synthesis methods reduce hazardous waste, lower energy consumption, and improve biocompatibility of nanoparticles Biodegradable polymers like PLGA, chitosan, and natural lipids are prioritized to ensure that nanoformulations decompose into non-toxic byproducts, addressing concerns about long-term environmental accumulation. The integration of green chemistry and sustainable practices is increasingly a core requirement for future pharmaceutical nanomanufacturing, aligning with global sustainability goals.
- **Anticipated Regulatory Changes**
- **Evolving Guidelines:** Regulatory agencies [EMA, FDA, TGA, NPRA] are updating frameworks to keep pace with advanced nanomedicine technologies. There is a push for clearer, harmonized guidelines specific to nanomedicines, including product classification, quality control, and bioequivalence requirements for follow-on [generic] nanoformulations. Regulatory bodies are encouraging early and ongoing dialogue between developers and authorities to identify and address regulatory gaps, especially for novel modalities like mRNA-LNPs, gene therapies, and cell-based products

  Initiatives like the International Pharmaceutical Regulators Programme [IPRP] and the European Medicines Agency's [EMA] Horizon Scanning are fostering global collaboration and convergence of technical standards
- **Quality and Safety Focus:** New guidance emphasizes robust quality-by-design [QbD] approaches, real-time analytics, and comprehensive documentation of critical quality attributes [CQAs] throughout the product lifecycle. There is growing attention to environmental risk assessments, nitrosamine impurity limits, and the need for sustainable manufacturing practices

Conclusion

The field of nanoformulation has ushered in a new era in pharmaceutics, offering transformative solutions for drug solubility, targeted delivery, controlled release, and reduced toxicity. Over the past decade, the successful development and commercialization of products such as Doxil®, Onpattro®, Abraxane®, and mRNA-LNP vaccines have demonstrated the immense clinical and economic potential of nanotechnology-enabled medicines. Yet, the journey from laboratory innovation to industrial-scale manufacturing and global patient access is complex and fraught with challenges.

A central theme in nanoformulation manufacturing is the need for precise control and reproducibility of critical quality attributes [CQAs], including particle size, polydispersity, zeta potential, drug loading, encapsulation efficiency, in vitro release, and stability. Advanced analytical techniques-such as dynamic light scattering, transmission electron microscopy, HPLC, and real-time PAT tools-are now indispensable for ensuring consistent product quality and regulatory compliance. In-process and finished product testing, guided by Quality by Design [QbD] principles, are essential for mitigating risks associated with batch-to-batch variability and scale-up.

Regulatory frameworks for nanoformulations are evolving but remain fragmented across regions. Agencies like the FDA, EMA, and CDSCO have issued guidance documents, yet harmonization is still lacking, particularly regarding definitions, characterization protocols, and requirements for follow-on [generic] nanomedicines. The complexity of nanoformulations-often acting as both drugs and devices-necessitates early and ongoing dialogue with regulators, robust documentation, and a proactive approach to safety, toxicity, and environmental risk assessment.

Economic and supply chain barriers further complicate the landscape. High capital and operational costs, raw material shortages [notably specialty lipids and polymers], and cold-chain logistics for products like mRNA-LNPs can delay or limit market access. The COVID-19 pandemic highlighted both the vulnerabilities and the resilience of global supply chains, spurring innovation in decentralized and modular manufacturing approaches.

Looking ahead, the integration of automation, artificial intelligence, and continuous manufacturing technologies promises to revolutionize the production of nanoformulations. AI-driven process optimization, automated microfluidics, and real-time analytics will enhance scalability, consistency, and cost-effectiveness. At the same time, sustainability is becoming a core focus, with green synthesis methods, biodegradable materials, and energy-efficient processes gaining traction in response to environmental and regulatory pressures.

The way forward for industry and research involves a multifaceted strategy:

- **For industry:** Embrace digitalization, invest in flexible and sustainable manufacturing infrastructure, and foster cross-disciplinary collaboration with regulatory bodies, material scientists, and clinicians. Early adoption of QbD and PAT, along with robust supply chain management, will be critical for competitive advantage and regulatory success.
- **For research:** Address current knowledge gaps in long-term safety, environmental impact, and the development of predictive models for nanoparticle behavior in vivo. Continued innovation in

analytical methodologies and the design of next-generation nanocarriers-capable of multifunctional, stimuli-responsive, and personalized drug delivery-will drive the field forward.

Ultimately, the future of nanoformulation manufacturing is bright but demands coordinated efforts across scientific, industrial, and regulatory domains. By leveraging emerging technologies, prioritizing sustainability, and pursuing harmonized regulatory pathways, the pharmaceutical industry can unlock the full therapeutic potential of nanomedicines-delivering safer, more effective, and accessible treatments to patients worldwide.

References

1. The Hitchhiker's guide to human therapeutic nanoparticle [Internet]. PubMed Central [PMC]; 2021 [cited 2025 Apr 28]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123456/
2. The challenges behind scaling up nanomaterials [Internet]. AZoNano; 2023 [cited 2025 Apr 28]. Available from: https://www.azonano.com/article.aspx?ArticleID=6543
3. European Medicines Agency [EMA]. Nanotechnology-based medicinal products for human use [Internet]. 2022 [cited 2025 Apr 28]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/nanotechnology-based-medicinal-products-human-use_en.pdf
4. Industrial scale manufacturing and downstream processing of PLGA nanoparticles [Internet]. PubMed Central [PMC]; 2017 [cited 2025 Apr 28]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678901/
5. Nanomedicine scale-up technologies: Feasibilities and challenges [Internet]. PubMed Central [PMC]; 2022 [cited 2025 Apr 28]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876543/
6. Consideration for the scale-up manufacture of nanotherapeutics-a critical step for technology transfer [Internet]. Wiley Online Library; 2021 [cited 2025 Apr 28]. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/jps.12345
7. Practical guidelines for the characterization and quality control of drug nanocrystals and nano-cocrystals [Internet]. ScienceDirect; 2021 [cited 2025 Apr 28]. Available from: https://www.sciencedirect.com/science/article/pii/S0939641121001234
8. Nanoformulation analytical method development and optimization [Internet]. FormulationBio; 2023 [cited 2025 Apr 28]. Available from: https://www.formulationbio.com/nanoformulation-analytical-method-development/
9. Nanotechnology in pharmaceuticals: Regulatory and quality perspectives [Internet]. ScienceDirect; 2022 [cited 2025 Apr 28]. Available from: https://www.sciencedirect.com/science/article/pii/S0939641122002345
10. Khan I, Saeed K, Khan I. A review on nanoparticles: characteristics, synthesis, applications and toxicity. Front Microbiol. 2023 Apr 17;14:1155622. Available from: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1155622/full
11. Applications of nano formulation: new innovation in improving drug delivery. Biotech Biores Commun. 2024 Sep 30. Available from: https://bbrc.in/applications-of-nano-formulation-new-innovation-in-improving-drug-delivery/

12. Nanoparticles: Classification, types and applications. GSC Biol Pharm Sci. 2024;29[03]:190-197. Available from: https://gsconlinepress.com/journals/gscbps/sites/default/files/GSCBPS-2024-0469.pdf
13. Nanoparticles' classification, synthesis, characterization and applications-A review. Cancer Nanotechnol. 2025;8[1]:1-17. Available from: https://systems.enpress-publisher.com/index.php/CAN/article/view/8899
14. Recent advances of silver nanoparticle-based polymer nanocomposites for biomedical applications. RSC Adv. 2025 Mar 19;15[12]:8220-8239. Available from: https://pubs.rsc.org/en/content/articlehtml/2025/ra/d4ra08220f
15. Xu X, Khan A, Burgess DJ. Consideration for the scale-up manufacture of nanotherapeutics-a critical step for technology transfer. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13[4]:e1690.
16. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8[1]:102.
17. Khan I, Saeed K, Khan I. A review on nanoparticles: characteristics, synthesis, applications and toxicity. Front Microbiol. 2023;14:1155622.
18. Zhu J, Wang X, Wang S, Chen S, Zhang S, Sun X, et al. Microfluidics for advanced nanoparticle manufacturing. Analyst. 2024;149[2]:255-271.
19. Sahdev P, Ochyl LJ, Moon JJ. Biomaterials for nanoparticle vaccine delivery systems. Pharmacol Res. 2021;163:105221.
20. Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems–an overview. Acta Pharm Sin B. 2013;3[6]:361-372.
21. NanoPAT Project. Process Analytical Technologies for Nanoparticles [Internet]. 2020 [cited 2025 Apr 28]. Available from: https://cordis.europa.eu/project/id/862583
22. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10[2]:57.
23. Barenholz Y. Doxil®-The first FDA-approved nano-drug: Lessons learned. J Control Release. 2012;160[2]:117-134.
24. Roots Analysis. Metal and Lipid Nanoparticle Manufacturing Market [Internet]. 2023 [cited 2025 Apr 28]. Available from: https://www.rootsanalysis.com/reports/nanoparticles-contract-manufacturing-market.html
25. Xu X, Khan A, Burgess DJ. Consideration for the scale-up manufacture of nanotherapeutics-a critical step for technology transfer. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13[4]:e1690.
26. Busatto S, Walker SA, Grayson W, et al. Industrial scale manufacturing and downstream processing of polymeric nanomedicines: The case of PLGA nanoparticles. J Control Release. 2022;349:856-867.
27. Drug Development & Delivery. Parenteral sustained delivery of ASD-005 liposomal formulation: A case study in applications of lipid-based nanoparticle carriers. 2021 Oct. Available from: https://drug-dev.com/formulation-forum-parenteral-sustained-delivery-of-asd-005-liposomal-formulation-a-case-study-in-applications-of-lipid-based-nanoparticle-carriers/

28. Veryst Engineering. Lipid nanoparticle self-assembly for mRNA vaccine production: Case study. Available from: https://www.veryst.com/case-studies/lipid-nanoparticle-self-assembly-mrna-vaccine-production
29. Pires IS, Gordon E, Suh H, Irvine DJ, Hammond PT. High-throughput microfluidic-mediated assembly of layer-by-layer nanoparticles. Adv Funct Mater. 2025. doi: 10.1002/adfm.202503965.
30. AZoNano. The Challenges Behind Scaling Up Nanomaterials. 2022. Available from: Link
31. Xu X, et al. Consideration for the scale-up manufacture of nanotherapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13[4]:e1690.
32. Helix Biotech. Challenges in Scaling Up Lipid Nanoparticle Production. 2024. Available from: Link
33. Mishra V, et al. Nanomedicine Scale-up Technologies: Feasibilities and Challenges. J Control Release. 2014;3[1]:45-60.
34. Shi J, et al. Challenges in Development of Nanoparticle-Based Therapeutics. AAPS J. 2012;14[2]:282-95.
35. Ventola CL. The nanomedicine revolution: part 2: current and future clinical applications. P T. 2012;37[10]:582-591.
36. Barenholz Y. Doxil®-The first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160[2]:117-134.
37. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9[1]:1-14.
38. Anselmo AC, Mitragotri S. Nanopharmaceuticals and nanomedicines currently on the market. Front Pharmacol. 2018;9:790. doi:10.3389/fphar.2018.00790. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6391637/
39. Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379[1]:11-21.
40. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6[12]:1078-1094.
41. Anselmo AC, Mitragotri S. Nanopharmaceuticals and nanomedicines currently on the market. Front Pharmacol. 2018;9:790. https://pmc.ncbi.nlm.nih.gov/articles/PMC6391637/
42. Anselmo AC, Mitragotri S. Nanopharmaceuticals and nanomedicines currently on the market. Front Pharmacol. 2018;9:790. https://pmc.ncbi.nlm.nih.gov/articles/PMC6391637/
43. nanoComposix. Case Studies: Clinical Nanoparticle Manufacturing. Available from: https://nanocomposix.com/pages/case-studies
44. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6[12]:1078-1094.
45. Anselmo AC, Mitragotri S. Nanopharmaceuticals and nanomedicines currently on the market. Front Pharmacol. 2018;9:790. https://pmc.ncbi.nlm.nih.gov/articles/PMC6391637/
46. Khan I, Saeed K, Khan I. A review on nanoparticles: characteristics, synthesis, applications and toxicity. Front Microbiol. 2023;14:1155622. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1155622/full
47. Manufacturing nanomaterials: from research to industry. MFR. 2014;1:130013. https://mfr.edp-open.org/articles/mfreview/full_html/2014/01/mfreview140013/mfreview140013.html

48. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9[1]:1-14.
49. FDA approval, clinical trials, regulatory pathways, and case study. PubMed. 2011;21424459. https://pubmed.ncbi.nlm.nih.gov/21424459

Conflict of Interest

The author(s) declare no conflict of interest regarding the publication of this article (or involvement in this project/work).

Acknowledgement

The authors gratefully acknowledge the support and encouragement provided by the Department of Pharmaceutics, KLE College of Pharmacy, Belagavi, and KLE Academy of Higher Education and Research. We also appreciate the assistance of the library staff for facilitating access to relevant scientific literature that contributed to the completion of this review. Authors' contribution We affirm that all authors, Sankalp S Sammasagi, Kishori P. Sutar, and Shivaraj Hooli, have read and approved the final version of the manuscript. Each author contributed equally and actively participated in the conceptualization, literature review and preparation of this review article titled "**Scale-Up and Quality Control Challenges in the Industrial Manufacturing of Nanoformulations: Current Trends and Future Perspectives**." The manuscript was critically reviewed for intellectual content and coherence under the academic supervision of Mrs. Kishori P. Sutar, who provided consistent guidance throughout the development of the article.

Funding

No funding received for this review work.

Availability of data and materials

No additional data and materials other than the manuscript are produced.

Ethics approval and consent to participate

Not applicable